ENTA Valuation

Enanta Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

4.260

-0.240(-5.330%)

Overview
Forecast
Valuation

ENTA Relative Valuation

ENTA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ENTA is overvalued; if below, it's undervalued.

Historical Valuation

Enanta Pharmaceuticals Inc (ENTA) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.54 is considered Undervalued compared with the five-year average of 7.57. The fair price of Enanta Pharmaceuticals Inc (ENTA) is between 8.65 to 27.76 according to relative valuation methord. Compared to the current price of 4.26 USD , Enanta Pharmaceuticals Inc is Undervalued By 50.74%.

Relative Value

Fair Zone

8.65-27.76

Current Price：4.26

50.74%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

0.86

P/B

Median3y

2.07

Median5y

2.28

-101.41

FCF Yield

Median3y

-32.41

Median5y

-20.22

Competitors Valuation Multiple

The average P/S ratio for ENTA's competitors is 2.38, providing a benchmark for relative valuation. Enanta Pharmaceuticals Inc Corp (ENTA) exhibits a P/S ratio of 1.54, which is -35.00% above the industry average. Given its robust revenue growth of -5.80%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

ENTA.O

Enanta Pharmaceuticals Inc